Abstract: Objective A systematic review was conducted to compare the efficacy and safety between β-blocker（βB） combined with calcium channel blocker（CCB） and combination of other two classe drug in patients with essential hypertension. Methods PubMed, EMBASE, Web of Science and Cochrane Library were searched for relevant randomized controlled trials（RCT） from inception until July 26, 2022. The primary efficacy endpoint included blood pressure（BP） control rate and the mean reduction of systolic BP（SBP）/diastolic BP（DBP） during the follow-up. The major safety outcome was the indidence rate of adverse drug reactions. Results A total of 9 RCT were included, and the analysis showed that the blood pressure control rate in βB+CCB group was not significantly different with other two-drug combination treatment group. SBP was significantly reduced in βB+CCB group compared with CCB+angiotensin converting enzyme inhibitor（ACEI）/angiotensin receptor blocker（ARB） group at the 3^rd month mean difference（MD）=-2.59（95%CI-4.97 to -0.21） mm Hg, P=0.03, 12^th month MD=-7.00（95%CI-10.75 to -3.25） mm Hg, P＜0.01 and 24^th month MD=-5.00（95%CI-8.84 to -1.16） mm Hg, P=0.01 of treatment. βB+CCB treatment significantly reduced heart rate at 12^th and 24^th month compared with other two-drug combinations treatment. No serious adverse reactions occurred in βB+CCB group or other two-drug combination treatment group, and there was no significant differences in adverse reactions between all groups. Conclusions Compared with other dual antihypertensive treatment, the combination of βB and CCB can significantly reduce SBP in the short term and brought about more pronounced long-term effects in lowering diastolic blood pressure and slowing heart rate.